<p>随着美国市场在不断上升的国债收益率和对联邦储备政策的不确定性中航行，投资者密切关注内部人士活动，作为公司增长前景信心的潜在指标。在这种气候下，拥有高内部人士持股的股票可能表明管理层与股东之间的强大一致性，这在市场条件波动时尤其吸引人。</p>
<h3>美国内部人士持股比例高的十大成长公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部人士持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微电脑 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们内部人士持股比例高的快速成长美国公司筛选器中的 209 只股票的完整列表。</p>
<p>我们将查看筛选工具中的一些最佳选择。</p>
<h2>CapsoVision (CV)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> CapsoVision, Inc. 是一家医疗技术公司，制造和销售用于胃肠系统成像的内窥镜视频成像设备，市值为 2.9183 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其胶囊内窥镜部门，金额为 1309 万美元。</p>
<p><strong>内部人士持股：</strong> 24.8%</p>
<p><strong>收益增长预测：</strong> 每年 56.4%。</p>
<p>CapsoVision 正在通过显著的内部人士持股推进其增长战略，专注于创新的诊断技术。该公司最近向 FDA 提交了 AI 辅助模块的 510(k) 申请，并有可能获得胰腺癌检测的突破性设备认证，突显其扩展产品线的承诺。尽管在 2025 年第三季度净亏损为 792 万美元，但收入同比增长 16.3%，预计未来三年内盈利能力将实现，因为收入预测显著超过市场。</p>
<ul>
<li>在这里深入了解 CapsoVision 的全面分析和未来增长报告。</li>
<li>我们的估值报告显示 CapsoVision 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月的 CV 持股分布</p>
<h2>Harrow (HROW)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Harrow, Inc. 是一家眼科制药公司，专注于发现、开发和商业化眼科药品，市值约为 17.7 亿美元。</p>
<p><strong>运营：</strong> Harrow 通过其品牌部门产生收入，金额为 1.6797 亿美元，以及其配方部门，贡献 8207 万美元。</p>
<p><strong>内部人士持股：</strong> 16.2%</p>
<p><strong>收益增长预测：</strong> 每年 45.4%。</p>
<p>Harrow 正在经历强劲增长，预计其收入将以每年 26.8% 的速度增长，超过美国市场。该公司报告 2025 年第三季度收入为 7164 万美元，较去年同期的 4926 万美元有所增长，并实现净收入为 102 万美元，而之前则是亏损。尽管交易价格显著低于估计的公允价值，并且缺乏最近的内部人士买卖数据，分析师预计股价将上涨 47.4%。</p>
<ul>
<li>在此增长报告中解锁我们对 Harrow 股票分析的全面见解。</li>
<li>根据我们的估值报告，Harrow 的股价可能偏低。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 1 月的 HROW 收益和收入增长</p>
<h2>Upstart Holdings (UPST)</h2>
<p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Upstart Holdings, Inc. 在美国运营一个基于云的 AI 贷款平台，市值约为 46.8 亿美元。</p>
<p><strong>运营：</strong> 公司的收入主要来自其个人贷款部门，产生 8688.2 万美元。</p>
<p><strong>内部人士持股：</strong> 12.6%</p>
<p><strong>收益增长预测：</strong> 每年 68.9%。</p>
<p>Upstart Holdings 在过去三个月内经历了大量内部人士买入，表明对其增长轨迹的信心。该公司最近实现盈利，报告 2025 年第三季度净收入为 3181 万美元，而之前则是亏损。预计收益将显著增长，年增长率为 68.87%，超过美国市场。尽管收入增长预测低于收益，但 Upstart 与 MyPoint 信用合作社和 Tech CU 等金融机构的合作增强了其市场存在感和扩展潜力。</p>
<ul>
<li>在这里通过我们的全面分析师估计报告深入了解 Upstart Holdings 的复杂性。</li>
<li>我们的全面估值报告提出 Upstart Holdings 的定价可能高于其财务状况所能证明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 1 月的 UPST 收益和收入增长</p>
<h2>抓住机会</h2>
<ul>
<li>点击这里深入了解 209 家内部人士持股比例高的快速成长美国公司的全貌。</li>
<li>对其他选择感到好奇？AI 即将改变医疗保健。这 110 只股票正在从早期诊断到药物发现等各个方面进行工作。最重要的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>

超微电脑

HROW

UPST

PROP

<p>随着美国市场面临不断上升的国债收益率和联邦储备的不确定性，内部人士活动被密切关注，作为公司增长信心的指标。内部持股比例高的股票，如超微电脑（Super Micro Computer，SMCI）和 Prairie Operating（PROP），因其潜力而受到关注。像 CapsoVision 和 Harrow 这样的公司显示出有希望的盈利增长预测，内部持股表明管理层的强大一致性。Upstart Holdings 经历了显著的内部人士买入，表明对其增长轨迹的信心。文章强调了在波动市场条件下，内部持股的重要性</p>

<p>As U.S. markets navigate a landscape of rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are keenly observing insider activities as a potential indicator of confidence in company growth prospects. In this climate, stocks with high insider ownership may signal strong alignment between management and shareholders, which can be particularly appealing when market conditions are volatile.</p>
<div class="lb-trans"><p>随着美国市场在不断上升的国债收益率和对联邦储备政策的不确定性中航行，投资者密切关注内部人士活动，作为公司增长前景信心的潜在指标。在这种气候下，拥有高内部人士持股的股票可能表明管理层与股东之间的强大一致性，这在市场条件波动时尤其吸引人。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美国内部人士持股比例高的十大成长公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>内部人士持股</strong></td>
<td><strong>收益增长</strong></td>
</tr>
<tr>
<td>超微电脑 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 209 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>点击这里查看我们内部人士持股比例高的快速成长美国公司筛选器中的 209 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中的一些最佳选择。</p>
</div><h2>CapsoVision (CV)</h2>
<div class="lb-trans"><h2>CapsoVision (CV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> CapsoVision, Inc. is a medical technology company that manufactures and markets endoscopic video imaging devices for gastrointestinal system imaging, with a market cap of $291.83 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> CapsoVision, Inc. 是一家医疗技术公司，制造和销售用于胃肠系统成像的内窥镜视频成像设备，市值为 2.9183 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its Capsule Endoscopy segment, amounting to $13.09 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其胶囊内窥镜部门，金额为 1309 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 24.8%</p>
<div class="lb-trans"><p><strong>内部人士持股：</strong> 24.8%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 56.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 56.4%。</p>
</div><p>CapsoVision is advancing its growth strategy with significant insider ownership, focusing on innovative diagnostic technologies. The company's recent 510(k) submission to the FDA for an AI-assisted module and potential Breakthrough Device Designation for pancreatic cancer detection highlight its commitment to expanding its product line. Despite a net loss of US$7.92 million in Q3 2025, revenue grew by 16.3% year-over-year, with future profitability expected within three years as revenue forecasts outpace the market significantly.</p>
<div class="lb-trans"><p>CapsoVision 正在通过显著的内部人士持股推进其增长战略，专注于创新的诊断技术。该公司最近向 FDA 提交了 AI 辅助模块的 510(k) 申请，并有可能获得胰腺癌检测的突破性设备认证，突显其扩展产品线的承诺。尽管在 2025 年第三季度净亏损为 792 万美元，但收入同比增长 16.3%，预计未来三年内盈利能力将实现，因为收入预测显著超过市场。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of CapsoVision.</li>
<li>Our valuation report here indicates CapsoVision may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 CapsoVision 的全面分析和未来增长报告。</li>
<li>我们的估值报告显示 CapsoVision 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown"/></p>
<p>CV Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 CV 持股分布</p>
</div><h2>Harrow (HROW)</h2>
<div class="lb-trans"><h2>Harrow (HROW)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Harrow, Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products with a market cap of approximately $1.77 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Harrow, Inc. 是一家眼科制药公司，专注于发现、开发和商业化眼科药品，市值约为 17.7 亿美元。</p>
</div><p><strong>Operations:</strong> Harrow generates revenue through its Branded segment, which accounts for $167.97 million, and its Compounding segment, contributing $82.07 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> Harrow 通过其品牌部门产生收入，金额为 1.6797 亿美元，以及其配方部门，贡献 8207 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 16.2%</p>
<div class="lb-trans"><p><strong>内部人士持股：</strong> 16.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 45.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 45.4%。</p>
</div><p>Harrow is experiencing strong growth, with its revenue forecasted to grow at 26.8% per year, outpacing the US market. The company reported Q3 2025 revenue of US$71.64 million, up from US$49.26 million a year ago, and achieved net income of US$1.02 million compared to a prior loss. Despite trading significantly below estimated fair value and lacking recent insider buying or selling data, analysts expect a stock price increase of 47.4%.</p>
<div class="lb-trans"><p>Harrow 正在经历强劲增长，预计其收入将以每年 26.8% 的速度增长，超过美国市场。该公司报告 2025 年第三季度收入为 7164 万美元，较去年同期的 4926 万美元有所增长，并实现净收入为 102 万美元，而之前则是亏损。尽管交易价格显著低于估计的公允价值，并且缺乏最近的内部人士买卖数据，分析师预计股价将上涨 47.4%。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Harrow stock in this growth report.</li>
<li>According our valuation report, there's an indication that Harrow's share price might be on the cheaper side.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此增长报告中解锁我们对 Harrow 股票分析的全面见解。</li>
<li>根据我们的估值报告，Harrow 的股价可能偏低。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth"/></p>
<p>HROW Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 HROW 收益和收入增长</p>
</div><h2>Upstart Holdings (UPST)</h2>
<div class="lb-trans"><h2>Upstart Holdings (UPST)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Upstart Holdings, Inc. operates a cloud-based AI lending platform in the United States and has a market cap of approximately $4.68 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Upstart Holdings, Inc. 在美国运营一个基于云的 AI 贷款平台，市值约为 46.8 亿美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its personal lending segment, which generated $868.82 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其个人贷款部门，产生 8688.2 万美元。</p>
</div><p><strong>Insider Ownership:</strong> 12.6%</p>
<div class="lb-trans"><p><strong>内部人士持股：</strong> 12.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 68.9% p.a.</p>
<div class="lb-trans"><p><strong>收益增长预测：</strong> 每年 68.9%。</p>
</div><p>Upstart Holdings has seen substantial insider buying over the past three months, indicating confidence in its growth trajectory. The company recently became profitable, reporting a Q3 2025 net income of US$31.81 million compared to a prior loss. Earnings are forecast to grow significantly at 68.87% per year, outpacing the US market. Despite revenue growth forecasts being slower than earnings, Upstart's partnerships with financial institutions like MyPoint Credit Union and Tech CU enhance its market presence and potential for expansion.</p>
<div class="lb-trans"><p>Upstart Holdings 在过去三个月内经历了大量内部人士买入，表明对其增长轨迹的信心。该公司最近实现盈利，报告 2025 年第三季度净收入为 3181 万美元，而之前则是亏损。预计收益将显著增长，年增长率为 68.87%，超过美国市场。尽管收入增长预测低于收益，但 Upstart 与 MyPoint 信用合作社和 Tech CU 等金融机构的合作增强了其市场存在感和扩展潜力。</p>
</div><ul>
<li>Navigate through the intricacies of Upstart Holdings with our comprehensive analyst estimates report here.</li>
<li>Our comprehensive valuation report raises the possibility that Upstart Holdings is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里通过我们的全面分析师估计报告深入了解 Upstart Holdings 的复杂性。</li>
<li>我们的全面估值报告提出 Upstart Holdings 的定价可能高于其财务状况所能证明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth"/></p>
<p>UPST Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 UPST 收益和收入增长</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Gain an insight into the universe of 209 Fast Growing US Companies With High Insider Ownership by clicking here.</li>
<li>Curious About Other Options? AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 209 家内部人士持股比例高的快速成长美国公司的全貌。</li>
<li>对其他选择感到好奇？AI 即将改变医疗保健。这 110 只股票正在从早期诊断到药物发现等各个方面进行工作。最重要的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们提供的评论基于历史数据和分析师预测，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成买卖任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。该分析仅考虑内部人士直接持有的股票，不包括通过其他工具（如公司和/或信托实体）间接持有的股票。所有引用的预测收入和盈利增长率均以年化（每年）增长率的形式表示，时间范围为 1-3 年。</em></p>
</div>

Insider-Owned Growth Stocks Poised For Success In January 2026

- 投资者关注美国高管持股的公司以判断增长潜力。  
- 提供美国高管持股前 10 名增长公司及其盈利增长率。  
- 提及 CapsoVision、Harrow 和 Upstart 的财务表现及未来增长预测。

内部人士持有的成长型股票在 2026 年 1 月有望取得成功